Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations

[1]  J. D. de Wilt,et al.  Inflammatory breast cancer: an overview. , 2015, Critical reviews in oncology/hematology.

[2]  J. Weeks,et al.  Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. , 2015, Clinical breast cancer.

[3]  Kathleen A Cronin,et al.  The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. , 2014, Cancer.

[4]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[5]  Daniel Birnbaum,et al.  Genomic profiling of inflammatory breast cancer: a review. , 2014, Breast.

[6]  P. Stephens,et al.  Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Yelensky,et al.  Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. , 2014 .

[8]  P. Stephens,et al.  A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. , 2014, The oncologist.

[9]  R. Yelensky,et al.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.

[10]  P. Stephens,et al.  Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. , 2014, Clinical breast cancer.

[11]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[12]  Sung-Bae Kim,et al.  A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. , 2013, European journal of cancer.

[13]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[14]  H. Lee,et al.  Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. , 2013, Human pathology.

[15]  M. Buyse,et al.  Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study , 2013, Cancer Chemotherapy and Pharmacology.

[16]  W. Woodward,et al.  Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma , 2013, SpringerPlus.

[17]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Park,et al.  Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women , 2013, PloS one.

[19]  James X. Sun,et al.  Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations , 2013, Clinical Cancer Research.

[20]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[21]  J. Rey,et al.  Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy , 2013, PloS one.

[22]  Fabrice Andre,et al.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. , 2013, Cancer discovery.

[23]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[24]  W. Woodward,et al.  Inflammatory breast cancer: what we know and what we need to learn. , 2012, The oncologist.

[25]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[26]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[27]  Paul D. Smith,et al.  Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer , 2012 .

[28]  R. Arriagada,et al.  Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. , 2012, International journal of radiation oncology, biology, physics.

[29]  Paul A. Rejto,et al.  An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 , 2012, Molecular Cancer Therapeutics.

[30]  Phillip E. C. Compeau,et al.  Why are de Bruijn graphs useful for genome assembly? , 2011, Nature Biotechnology.

[31]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[32]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[33]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Melissa Bondy,et al.  Inflammatory Breast Cancer: The Disease, the Biology, the Treatment , 2010, CA: a cancer journal for clinicians.

[35]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[36]  Hong Liu,et al.  Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.

[37]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[38]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[39]  A. Buzdar,et al.  Evolving novel anti-HER2 strategies. , 2009, The Lancet. Oncology.

[40]  P. Levine,et al.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.

[41]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[42]  Olufunmilayo I Olopade,et al.  MYC in breast tumor progression , 2008, Expert review of anticancer therapy.

[43]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[44]  F. Cappuzzo,et al.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.

[45]  W. Park,et al.  Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.

[46]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[47]  M. Dowsett,et al.  High incidence of HER-2 positivity in inflammatory breast cancer. , 2004, Breast.

[48]  S. Liauw,et al.  Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease , 2004, Cancer.

[49]  M. Espié,et al.  Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C. Galmarini,et al.  Clinical Outcome and Prognosis of Patients With Inflammatory Breast Cancer , 2002, American journal of clinical oncology.

[51]  M. Henderson,et al.  Secondary Inflammatory Breast Cancer: Treatment Options , 1988, Southern medical journal.

[52]  C. Williams.  Inflammatory breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Teitelbaum,et al.  Inflammatory carcinoma of the breast. A Pathologic Definition , 1974, Cancer.

[54]  P. Rosen.  Inflammatory carcinoma of the breast. , 1970, Rocky Mountain medical journal.

[55]  J. Siegel.  Inflammatory carcinoma of the breast. , 1952, A.M.A. archives of dermatology and syphilology.

[56]  J. Marshall,et al.  Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. , 2015, Current cancer drug targets.

[57]  P. Stephens,et al.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. , 2015, The oncologist.

[58]  T. Kang,et al.  Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. , 2014, Drug discovery today.

[59]  G. Batist,et al.  Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.